On August 27, 2025, the Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), will host a hybrid public meeting on "Demand Forecasting for Controlled Substances.” This meeting will include exploration of the complex factors that are considered when estimating the medical, scientific, and reserve stock needs for Schedule I and Schedule II substances, such as opioids and stimulants.